Home/Filings/4/0001127602-19-012198
4//SEC Filing

PANGIA ROBERT W 4

Accession 0001127602-19-012198

CIK 0000875045other

Filed

Mar 18, 8:00 PM ET

Accepted

Mar 19, 4:08 PM ET

Size

8.9 KB

Accession

0001127602-19-012198

Insider Transaction Report

Form 4
Period: 2019-03-18
Transactions
  • Sale

    Common Stock

    2019-03-18$328.55/sh6,114$2,008,75518,587 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2019-03-186,1140 total
    Exercise: $53.43From: 2010-06-03Exp: 2019-06-02Common Stock (6,114 underlying)
  • Exercise/Conversion

    Common Stock

    2019-03-18$52.22/sh+6,114$319,27324,701 total
Footnotes (3)
  • [F1]Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
  • [F2]This option was previously reported as covering 5,975 shares at an exercise price of $53.43 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.
  • [F3]Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC Rule 16(b)-3(d).

Issuer

BIOGEN INC.

CIK 0000875045

Entity typeother

Related Parties

1
  • filerCIK 0001236188

Filing Metadata

Form type
4
Filed
Mar 18, 8:00 PM ET
Accepted
Mar 19, 4:08 PM ET
Size
8.9 KB